Drug Profile
Research programme: sublingual immunotherapies - Planet Biopharmaceuticals
Latest Information Update: 17 Feb 2014
Price :
$50
*
At a glance
- Originator Antigen Laboratories; Planet Biopharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic asthma; Allergic rhinitis
Most Recent Events
- 08 Jan 2014 Antigen Laboratories withdraws a phase II trial for Allergic rhinitis in USA (NCT00670384)
- 19 Jun 2013 No development reported - Preclinical for Allergic asthma in USA (Sublingual)
- 19 Jun 2013 No development reported - Preclinical for Allergic rhinitis in USA (Sublingual)